Nivolumab With DC Vaccines for Recurrent Brain Tumors
Status:
Completed
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will
receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab
alone and with DC vaccine therapy until surgical resection. During surgical resection blood
and tumor samples will be assessed and compared. Following surgery, both groups will continue
to receive DC vaccines (total of 8) and nivolumab therapy until confirmed progression.